Albumin Infusion Improves Outcomes of Patients With Spontaneous Bacterial Peritonitis: A Meta-analysis of Randomized Trials

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 2, 2013, Pages

  Salerno, Francesco ^a   Navickis, Roberta J ^b   Wilkes, Mahlon M ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b Hygeia Associates   (United States)

Author keywords

Ascites; ; Cirrhosis; ; Infection; ; Kidney Failure

Indexed keywords

ALBUMIN; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; CREATININE;

ARTICLE; BACTERIAL PERITONITIS; COCHRANE LIBRARY; CREATININE BLOOD LEVEL; EMBASE; HUMAN; KIDNEY DYSFUNCTION; MEDLINE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PUBLICATION; SYSTEMATIC REVIEW;

EID: 84872413960     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.11.007     Document Type: Article

References (43)

1. Fernández J., Navasa M., Gómez J., et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002, 35:140-148.
2. Follo A., Llovet J.M., Navasa M., et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994, 20:1495-1501.
3. Bonnel A.R., Bunchorntavakul C., Reddy K.R. Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol 2011, 9:727-738.
4. Bories P.N., Campillo B., Azaou L., et al. Long-lasting NO overproduction in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 1997, 25:1328-1333.
5. Navasa M., Follo A., Filella X., et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998, 27:1227-1232.
6. Ruiz-del-Arbol L., Urman J., Fernández J., et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003, 38:1210-1218.
7. Ginès P., Schrier R.W. Renal failure in cirrhosis. N Engl J Med 2009, 361:1279-1290.
8. Arroyo V., Fernandez J., Ginès P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008, 28:81-95.
9. Tandon P., Garcia-Tsao G. Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol 2011, 9:260-265.
10. Quinlan G.J., Martin G.S., Evans T.W. Albumin: biochemical properties and therapeutic potential. Hepatology 2005, 41:1211-1219.
11. Sort P., Navasa M., Arroyo V., et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999, 341:403-409.
12. Runyon B.A. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009, 49:2087-2107.
13. Ginès P., Angeli P., Lenz K., et al. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010, 53:397-417.
14. Egger M., Davey Smith G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
15. Altman D.G., Bland J.M. Interaction revisited: the difference between two estimates. BMJ 2003, 326:219.
16. Jüni P., Altman D.G., Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001, 323:42-46.
17. Xue H.P., Lin B., Zhong J., et al. Effect of albumin infusion on preventing the deterioration of renal function in patients with spontaneous bacterial peritonitis. Chin J Dig Dis 2002, 3:32-34.
18. Fernández J., Monteagudo J., Bargallo X., et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005, 42:627-634.
19. Chen T.A., Tsao Y.C., Chen A., et al. Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis. Scand J Gastroenterol 2009, 44:619-625.
20. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
21. Moher D., Tetzlaff J., Tricco A.C., et al. Epidemiology and reporting characteristics of systematic reviews. PLoS Med 2007, 4:e78.
22. Fleiss J.L. The statistical basis of meta-analysis. Stat Methods Med Res 1993, 2:121-145.
23. Perdomo Coral G., Alves de Mattos A. Renal impairment after spontaneous bacterial peritonitis: incidence and prognosis. Can J Gastroenterol 2003, 17:187-190.
24. Sigal S.H., Stanca C.M., Fernandez J., et al. Restricted use of albumin for spontaneous bacterial peritonitis. Gut 2007, 56:597-599.
25. Narula N., Tsoi K., Marshall J.K. Should albumin be used in all patients with spontaneous bacterial peritonitis?. Can J Gastroenterol 2011, 25:373-376.
26. Oxman A.D., Guyatt G.H. A consumer's guide to subgroup analyses. Ann Intern Med 1992, 116:78-84.
27. Wang R., Lagakos S.W., Ware J.H., et al. Statistics in medicine: reporting of subgroup analyses in clinical trials. N Engl J Med 2007, 357:2189-2194.
28. Sun X., Briel M., Walter S.D., et al. Is a subgroup effect believable? updating criteria to evaluate the credibility of subgroup analyses. BMJ 2010, 340:c117.
29. Terg R., Gadano A., Cartier M., et al. Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study. Liver Int 2009, 29:415-419.
30. Poca M., Concepción M., Casas M., et al. Role of albumin treatment in patients with spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol 2012, 10:309-315.
31. de Araujo A., de Barros Lopes A., Rossi G., et al. Low-dose albumin in the treatment of spontaneous bacterial peritonitis: should we change the standard treatment?. Gut 2012, 61:1371-1372.
32. Bernardi M., Caraceni P., Navickis R.J., et al. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology 2012, 55:1172-1181.
33. Arroyo V., Fernandez J. Pathophysiological basis of albumin use in cirrhosis. Ann Hepatol 2011, 10(Suppl 1):S6-S14.
34. Jürgens G., Müller M., Garidel P., et al. Investigation into the interaction of recombinant human serum albumin with Re-lipopolysaccharide and lipid A. J Endotoxin Res 2002, 8:115-126.
35. Fukui H., Tsujita S., Matsumoto M., et al. Endotoxin inactivating action of plasma in patients with liver cirrhosis. Liver 1995, 15:104-109.
36. Stadlbauer V., Mookerjee R.P., Wright G.A., et al. Role of Toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis. Am J Physiol Gastrointest Liver Physiol 2009, 296:G15-G22.
37. Nathan C., Xie Q.W., Halbwachs-Mecarelli L., et al. Albumin inhibits neutrophil spreading and hydrogen peroxide release by blocking the shedding of CD43 (sialophorin, leukosialin). J Cell Biol 1993, 122:243-256.
38. Marley R., Patel R.P., Orie N., et al. Formation of nanomolar concentrations of S-nitroso-albumin in human plasma by nitric oxide. Free Radic Biol Med 2001, 31:688-696.
39. Groeneveld A.B., Navickis R.J., Wilkes M.M. Update on the comparative safety of colloids: a systematic review of clinical studies. Ann Surg 2011, 253:470-483.
40. Zarychanski R., Turgeon A.F., Fergusson D.A., et al. Renal outcomes and mortality following hydroxyethyl starch resuscitation of critically ill patients: systematic review and meta-analysis of randomized trials. Open Med 2009, 3:E196-E209.
41. Dart A.B., Mutter T.C., Ruth C.A., et al. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 2010, 1. CD007594.
42. Christidis C., Mal F., Ramos J., et al. Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions. J Hepatol 2001, 35:726-732.
43. Bradburn M.J., Deeks J.J., Berlin J.A., et al. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007, 26:53-77.